Company's Philosophy on Code of Corporate Governance
Bafna Pharma’s philosophy on corporate governance envisages working towards high levels of transparency,
accountability, consistent value systems, and delegation across all facets of its operations leading
professionally focused methods and management processes by upholding “Quality” as our end objective. Our
brand image and unflinching commitment to “Quality” are intrinsically linked; to reach this desired
destination we employ honest and ethical business practices such as operational transparency across all
levels, individual accountability, planned delegation across various staff levels and the opportunity
for open communication between the staff, management and stakeholders, including shareholders,
employees, customers, suppliers and statutory authorities. Bafna Pharma is committed to learn and adopt
the best practices of corporate governance.
Board of Directors
The Board comprises 6 Directors, out of which 1 is Executive Director, 2 are Non- Executive Directors
(Non-Independent) and 3 Non-Executive Directors ( Independent).
The names and category of Directors are given below:
|
|
Name of
Director
|
Designation
/ Category
|
|
|
|
|
Ms.
S Hemalatha
|
Whole-Time Director
|
|
|
|
|
Mr.
B Kamlesh Kumar
|
Non-Executive Independent Director
|
|
|
|
|
Mr.
P K Sundaresan
|
Non-Executive Independent Director
|
|
|
|
|
Mrs.
Ravichandran Chitra
|
Non-Executive Independent Director
|
|
|
|
|
Mrs.
AkilaPriya C. Raju
|
Non-Executive (Non- Independent Director)
|
|
|
|
|
Mr.
Atul Sachdeva
|
Non-Executive (Non- Independent Director)
|
|
|
|
Independent Directors
- Mr. B Kamlesh Kumar
- Mr. P K Sundaresan
- Mrs. Ravichandran Chitra
APPOINTMENT LETTERS TO INDEPENDENT DIRECTORS
FAMILIARIZATION PROGRAM FOR INDEPENDENT DIRECTORS
Audit Committee
The terms of reference of the Audit Committee cover the matters specified under SEBI (Listing Obligations
and Disclosure Requirements) Regulations 2015 . The constitution of Audit Committee also meets with the
requirements under Section 177 of the Companies Act, 2013.
The composition of the Audit Committee with effect from 12.11.2020 is as follows:
|
|
Sl No
|
Name of
Director
|
Designation
|
|
|
|
|
1
|
Mr.
P K Sundaresan
|
Chairman
|
|
|
|
|
2
|
Mr.
B Kamlesh Kumar
|
Member
|
|
|
|
|
3
|
Mr.
Atul Sachdeva
|
Member
|
|
|
|
The role of the audit committee shall include the following:
- Oversight of the listed entity’s financial reporting process and the disclosure
of its financial information to ensure that the financial statement is correct, sufficient and
credible;
- Recommendation for appointment, remuneration and terms of appointment of auditors
of the listed entity;
-
- Reviewing, with the management, the annual financial statements and auditor's
report thereon before submission to the board for approval, with particular reference to:
- (a) Matters required to be included in the director’s responsibility statement to be included in
the board’s report in terms of clause (c) of sub-section (3) of Section 134 of the Companies Act,
2013;
- (b) Changes, if any, in accounting policies and practices and reasons for the same;
- (c) Major accounting entries involving estimates based on the exercise of judgment by management;
- (d) Significant adjustments made in the financial statements arising out of audit findings;
- (e) Compliance with listing and other legal requirements relating to financial statements;
- (f) Disclosure of any related party transactions;
- (g) Modified opinion(s) in the draft audit report;
- Reviewing, with the management, the statement of uses / application of funds
raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of
funds utilized for purposes other than those stated in the offer document / prospectus / notice and
the report submitted by the monitoring agency monitoring the utilisation of proceeds of a public or
rights issue, and making appropriate recommendations to the board to take up steps in this matter;
- Reviewing and monitoring the auditor’s independence and performance, and
effectiveness of audit process
- Approval or any subsequent modification of transactions of the listed entity with
related parties;
- Scrutiny of inter-corporate loans and investments;
- Valuation of undertakings or assets of the listed entity, wherever it is
necessary;
- Evaluation of internal financial controls and risk management systems;
- Reviewing, with the management, performance of statutory and internal auditors,
adequacy of the internal control systems;
- Reviewing the adequacy of internal audit function, if any, including the
structure of the internal audit department, staffing and seniority of the official heading the
department, reporting structure coverage and frequency of internal audit;
- Discussion with internal auditors of any significant findings and follow up there
on;
- Reviewing the findings of any internal investigations by the internal auditors
into matters where there is suspected fraud or irregularity or a failure of internal control systems
of a material nature and reporting the matter to the board;
- Discussion with statutory auditors before the audit commences, about the nature
and scope of audit as well as post-audit discussion to ascertain any area of concern;
- To look into the reasons for substantial defaults in the payment to the
depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and
creditors;
- To review the functioning of the whistle blower mechanism;
- Approval of appointment of chief financial officer after assessing the
qualifications, experience and background, etc. of the candidate;
- Carrying out any other function as is mentioned in the terms of reference of the
audit committee.